SCHEDULE 13G: Intracoastal Capital Group Discloses 4.99% Passive Stake in Enveric Biosciences
Beneficial Ownership Statement
A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a passive beneficial ownership of 4.99% in Enveric Biosciences, Inc. common stock.
Summary
- Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership in Enveric Biosciences, Inc.
- As of February 5, 2025, the Reporting Persons collectively beneficially own 103,951 shares of Enveric Biosciences, Inc. common stock.
- This ownership represents approximately 4.99% of the company's common stock.
- The shares are primarily issuable upon the exercise of Intracoastal Warrant 2, with shared voting and dispositive power.
- The filing notes that the beneficial ownership percentage is limited by 'blocker provisions' within the warrants, which prevent exercise beyond certain thresholds (e.g., 4.99% or 9.99%) to avoid exceeding beneficial ownership limits.
- Without these blocker provisions, the Reporting Persons could have been deemed to beneficially own 286,001 shares of Common Stock as of February 5, 2025.
- The initial beneficial ownership following a Securities Purchase Agreement (SPA) on January 30, 2025, was 76,867 shares, representing approximately 9.99% of the common stock at that time, also subject to blocker provisions.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. The presence of an institutional investor taking a significant stake, even if passive and subject to blocker provisions, can be viewed as a neutral to slightly positive signal by the market, indicating some level of investor interest.
Future Outlook
The document does not provide any forward-looking statements or guidance from Enveric Biosciences, Inc. or the Reporting Persons regarding the company's future operations or financial performance.
Industry Context
This Schedule 13G filing indicates a significant passive investment by an institutional group in Enveric Biosciences, Inc., a company whose common stock is publicly traded. Such filings are standard disclosures for investors acquiring a beneficial ownership stake above 5% and typically do not provide broader industry context.
Related Party Transactions
- The Securities Purchase Agreement (SPA) between Enveric Biosciences, Inc. and Intracoastal Capital LLC (and its affiliates) represents a transaction between the company and a significant investor group.
Stakeholder Impact
- Shareholders: The filing indicates a significant stake held by an institutional investor group, which can influence market perception and potentially future trading activity. The existence of warrants and their exercise could lead to dilution of existing shareholders if not already accounted for in the share count.
Key Dates
| Date | Description |
|---|---|
| 01/30/2025 | Date of event which requires filing of this statement; execution of the Securities Purchase Agreement (SPA) with Enveric Biosciences, Inc. |
| 02/03/2025 | Date of Form 8-K filing by Enveric Biosciences, Inc. disclosing the SPA. |
| 02/05/2025 | Date of filing of this Schedule 13G statement and the beneficial ownership calculation date. |
Keywords
Enveric Biosciences, Schedule 13G, Beneficial Ownership, Intracoastal Capital, Common Stock, Warrants, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.